Bornstein-Quevedo L, García-Vázquez FJ, López-Corella E

Language: Spanish
References: 29
Page: 176-182
PDF size: 434.08 Kb.

ABSTRACT

Background. The current classification of anaplastic large cell lymphoma (ALCL) and the correlation of T or B cell lineage with ALK expression are controversial. Although ALCL represents 15% of pediatric lymphomas, the morphologic and immunohistochemical features are not well characterized.
Methods. All large cell lymphomas with anaplastic features accessioned in the surgical pathology files between 1980 and 2002 were studied. Immunophenotyping was performed to identify the ALK+ ALCL.
Results. Fifteen cases were evaluated, seven were ALK-negative (three Hodgkin lymphomas, and four diffuse large B-cell lymphomas). Eight ALK+, CD30+ ALCL with T/null cell immunophenotype were identified in five boys and three girls (median eight years). Immunostaining with CD30 and EMA was observed in 100 and 87% of cases, respectively. Two of the eight ALCL´s had ALK staining restricted to the cytoplasm. Six cases showed T-cell phenotype while only two were considered null-type.
Conclusions. ALK positive ALCL´s are frequent (53%) among large cell lymphomas with anaplastic features. Most of them express CD30, EMA and generic T-cell markers. The use of ALK protein helps to recognize a subgroup of large cell lymphomas.

REFERENCES

1. Grovas A, Fremgen A, Rauch A, Ruymann FB, Hutchinson CL, Winchester DP, Menck HR. The National Cancer database report on patterns of childhood cancer in the United States. Cancer 1997;80:2321-32.

2. Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N. Large cell non-Hodgkin lymphoma of childhood. Cancer 2000;88:186-97.

3. Murphy SB. Pediatric lymphomas: recent advances and commentary on Ki-1 positive anaplastic large cell lymphoma of childhood. Ann Oncol 1994;5:S1.

4. Wright D, Mc Keever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: Findings from de UK Children´s Cancer Study. J Clin Pathol 1997;50:128-35.

5. Schwab U, Stein H, Lemke H, Kirchner H, Schaadt M. Production of a monoclonal antibody specific for Hodgkin and Reed-Sternberg cells of Hodgkin´s disease and a subset of normal lymphoid cells. Nature 1982;299:65-7.

6. Jaffe ES. Anaplastic large cell lymphoma: The shifting sands of diagnostic hematopathology. Mod Pathol 2001;14:219-28.

7. Stein H, Mason DY, Gardes J, O´Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K. The expression of Hodgkin´s disease associated Ki-1 antigen in reactive and neoplastic lymphoid tissues: evidence that Sternberg-Reed cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58.

8. Rimokh R, Magaud JP, Berger F, Samarnt J, Coiffer B, Germain D, Mason DY. A translocation involving the specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (“Ki-1 lymphoma”). Br J Hematol 1989;71:31-40.

9. Stansfeld A, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszeska O, Noel H, Rilke F, Sundstrom C, Van Unnik J, Wright D. Updated Kiel classification for lymphomas. Lancet 1988;1;292-301.

10. Harris NL, Jaffe ES, Stein H, Banks P, Chan JKC, Cleary ML, Delsol G, De Wolf Peters C, Falini B, Gatter KC, Grogan TM, Issacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Ralfkier E, Warnke RA. A revised European American classification of lymphoid neoplasms: A proposal for the International Lymphoid Study Group. Blood 1994;84:1361-70.

11. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics. Tumours of Hematopoietic and Lymphoid Tissues. World Health Organization of Tumours. IARCPress, Lyon. 2001.

12. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G. ALK-positive Lymphoma: A single disease with a broad spectrum of morphology. Blood 1998;91:2076-84.

13. Pireli S, Falini B, Delsol G, Stein H, Baglioni P, Poggi S. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki1+) with a high content of reactive histiocytes. Histopathol 1990;16:383-91.

14. Kinney M, Collins M, Greer J, Whitlock J, Sioutos N, Kadin M. A small-cell-predominant variant of primary Ki-1 (CD30) + T-cell lymphoma. Am J Surg Pathol 1993;17:859-68.

15. Haralambieva E, Pulford KA, Lamant L, Pileri S, Roncador G, Gatter KC, Delsol G, Mason DY. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphoma. Br J Hematol 2000;109:584-91.

16. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of the kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin´s lymphoma. Science 1994;263:1281-90.

17. Bitter MA, Franklin WA, Larson RA, McKeithan TW, Rubin CM, Le Beau MM, Stephens JK, Vardiman JW. Morphology in Ki-1 (CD30) positive non-Hodgkin´s lymphoma is correlated with clinical features and a unique chromosomal abnormality, t(2;5)(p23;q35) Am J Surg Pathol 1990;14:305-16.

18. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takashita M, Mori N, Fujimoto J. Anaplastic large cell lymphoma expressing the novel chimeric protein p80NPM/ALK. A distinct clinicopathologic entity. Blood 1995;86:1954-60.

19. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L. ALK expression defines a disntict group of T/Null lymphomas (“ALK Lymphomas”) with a wide morphological spectrum. Am J Pathol 1998;153:875-86.

20. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ Lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697-706.

21. Sanddlund J, Pui C, Roberts W. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 1994;84:2467-71.

22. Gordon B, Weisenburger D, Warkentin P, et al. Peripheral T-cell lymphoma in childhood and adolescence. Cancer 1993;71:257-63.

23. Hutchinson RE, Banki K, Shuster J, Barrett D, Dieck C, Bernard CW, Murphy B, Link P, Laver J, Schwenn M, Mathew P, Morris SW. Use of the anti-ALK antibody in the characterization of anaplastic large cell lymphoma of childhood. Ann Oncol 1997;8:S37-S42.

24. Sherman CG, Zielenska M, Lorenzana AN, Pulford K, Mason DY, Hutchinson RE, Thorner PS. Morphological and phenotypic features in pediatric large cell lymphoma and their correlation with ALK expression and the t(2;5)(p23;q35). Pediatr Develop Pathol 2001;4:129-37.

25. Nakamura Sh, Shiota M, Nakagawa A, Yatabe Y, Kijima M, Motoori T, Suzuki R, Kagami Y. Anaplastic large cell lymphoma: A distinct molecular pathologic entity. Am J Surg Pathol 1997;21:1420-32.

26. Delsol G, Al Saati T, Gatter KC, Gerdes J, Schwiarting R, Caveriviere P, Rigal-Huguet F, Robert A, Stein H, Mason DY. Coexpression of epithelial membrane antigen (EMA), Hi-1 and interleukin-2 receptor by anaplastic large cell lymphoma. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988;130:39-45.

27. Hilkens J, Ligtenberg MJL, Vos HL, Litvinov SV. Cell membrane associated mucins and their adhesion-modulating properties. Trend Biochem Sci 1992;17:359-63.

28. Pulford K, Lammant I, Morris S. Detection of anaplastic large cell lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)- ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89:1394-04.

29. Bornstein-Quevedo L, Lehmann L, Vargas SO, Kosakewich HPW, Perez-Atayde AR. ALK+ Anaplastic large cell lymphoma in children. A clinicopathologic analysis. Mod Pathol 2003;16:1P.